京尼平苷对阿霉素所致小鼠心脏毒性的保护作用

Geniposide Protects against Doxorubicin-induced Cardiotoxicity in Mice

目的研究京尼平苷对阿霉素所致小鼠心脏毒性的保护作用。方法昆明种小鼠随机分为正常对照组、阿霉素组、阿霉素+京尼平苷小剂量组和阿霉素+京尼平苷大剂量组,后三组腹腔注射阿霉素2mg/kg,隔天一次,共10次。计算心脏体质量比,检测血清中乳酸脱氢酶(LDH)和肌酸激酶(CK)等生化指标,苏木素-伊红(HE)染色法检测心肌组织结构的变化情况。结果与正常对照组比较,阿霉素组存活率下降,心脏体质比增加,LDH和CK释放增加(P<0.05),HE染色显示心肌纤维结构紊乱,心肌间隙变大;与阿霉素组比较,大剂量京尼平苷对存活率没有影响,但是降低心脏体质比(P<0.05),减少LDH和CK的释放(P<0.05),心肌结构也有较大的改善;小剂量京尼平苷对存活率和LDH及CK都没有影响,但是减少心脏体质比(P<0.05),对心肌结构有轻微的改善。结论京尼平苷能保护阿霉素引起的心肌毒性,可能与减少LDH和CK的释放,以及改善心肌组织结构有关。此研究将为减少阿霉素的心脏副作用提供新的治疗药物。

Objective To study the protective effect of geniposide against doxorubicin-induced cardiotoxicity.Methods Kunming mice were randomly divided into the control group,doxorubicin group,geniposide low-dose group and high-dose group.The animals in doxorubicin group,geniposide low-dose group and geniposide high-dose group were injected intraperitoneal doxorubicin(2 mg/kg,once for two days)for 10 times.The surviving mice were weighed and taken for next experiments.The cardiac body mass ratio(heart/body weight)was calculated and LDH and CK in serum were also detected,and morphological hematoxylin-eosin(HE)staining was measured for changes in myocardial tissue structure.Results Compared with the normal control group,the survival rate of the doxorubicin group was decreased;the body mass ratio was increased;the release of LDH and CK was increased(P<0.05);furtherly,the myocardial fiber structure was morphologically disordered and the myocardial space became larger.Compared with the doxorubicin group,the administration of large doses of geniposide had no effect on the survival rate,but the heart-to-body ratio was decreased(P<0.05);the release of LDH and CK was decreased(P<0.05);but,low-dose geniposide had no effect on survival rate and LDH and CK with the decrease of cardiac body mass ratio(P<0.05)and slightly improved myocardial structure.Conclusion Geniposide can protect myocarditis caused by doxorubicin,which may be related to the reduction of LDH and CK release and the improvement of myocardial tissue structure.New therapeutic drugs will be provided to reduce the side effects of doxorubicin.